\
&
Contact us
As a co-programmed partnership, BATT4EU brings together the public sector (the European Commission) and the private sector (the European battery R&I stakeholders, BEPA) with the aim to achieve a competitive and sustainable European industrial value-chain for e-mobility and stationary applications.
BEPA already gathers a total of 137 members of which 54 are industrial players, 56 research organisations, 27 associations, and others.
Aside from some general objectives, the Batteries Partnership (BATT4EU) has various measurable, operational objectives:
Operational objectives:
Partnerships group the EC and private and/or public partners, to coordinate and streamline the research & innovation initiatives and funding in some selected key domains.
Ria.debreucker@vlaio.be
The METHYLOMIC project, ‘targeting hope for personalised medicine in immune-mediated inflammatory diseases’ obtained funding from Horizon Europe’s Health Cluster. The project aims to personalise treatment allocation and enhance the effectiveness of medications for chronic immune-mediated diseases such as Crohn’s disease, rheumatoid arthritis, and psoriasis. BIRD, the Belgian inflammatory bowel disease research and development group, is a partner in the project and is involved in the OmiCrohn trial, a prospective randomised clinical trial for individualised therapy in Crohn’s disease patients. With BIRD’s active role in this trial, the project is set to deliver predictive, biomarker-based therapies that bring renewed hope for Crohn’s disease patients across Europe.